{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:37:30Z","timestamp":1790699850918,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00432-023-04621-5","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T20:09:10Z","timestamp":1675886950000},"page":"6361-6370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case"],"prefix":"10.1007","volume":"149","author":[{"given":"Min","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"4621_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","volume":"17","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP et al (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol 17:883\u2013895. https:\/\/doi.org\/10.1016\/S1470-2045(16)30098-5","journal-title":"Lancet Oncol"},{"key":"4621_CR2","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"key":"4621_CR3","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1158\/1078-0432.CCR-12-1153","volume":"18","author":"DE Bauer","year":"2012","unstructured":"Bauer DE, Mitchell CM, Strait KM, Lathan CS, Stelow EB, L\u00fcer SC et al (2012) Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 18:5773\u20135779. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1153","journal-title":"Clin Cancer Res"},{"key":"4621_CR4","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.5301\/tj.5000685","volume":"103","author":"S Cavalieri","year":"2017","unstructured":"Cavalieri S, Stathis A, Fabbri A, Sonzogni A, Perrone F, Tamborini E et al (2017) Uncommon somatic mutations in metastatic NUT midline carcinoma. Tumori 103:e5\u2013e8. https:\/\/doi.org\/10.5301\/tj.5000685","journal-title":"Tumori"},{"key":"4621_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00428-020-03011-3","volume":"478","author":"K Chatzopoulos","year":"2021","unstructured":"Chatzopoulos K, Boland JM (2021) Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors. Virchows Arch 478:21\u201330. https:\/\/doi.org\/10.1007\/s00428-020-03011-3","journal-title":"Virchows Arch"},{"key":"4621_CR6","doi-asserted-by":"publisher","first-page":"pkz094","DOI":"10.1093\/jncics\/pkz094","volume":"4","author":"NG Chau","year":"2019","unstructured":"Chau NG, Ma C, Danga K, Al-Sayegh H, Nardi V, Barrette R et al (2019) An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients. JNCI Cancer Spectr 4:pkz094. https:\/\/doi.org\/10.1093\/jncics\/pkz094","journal-title":"JNCI Cancer Spectr"},{"key":"4621_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.humpath.2021.02.004","volume":"115","author":"M Chen","year":"2021","unstructured":"Chen M, Yang J, Lv L, Li Y, Tang Y, Liu W et al (2021) Comprehensive genetic profiling of six pulmonary nuclear protein in testis carcinomas with a novel micropapillary histological subtype in two cases. Hum Pathol 115:56\u201366. https:\/\/doi.org\/10.1016\/j.humpath.2021.02.004","journal-title":"Hum Pathol"},{"key":"4621_CR8","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00428-021-03253-9","volume":"480","author":"M Chen","year":"2022","unstructured":"Chen M, Zhao S, Liang Z, Wang W, Zhou P, Jiang L (2022) NUT carcinoma of the parotid gland: report of two cases, one with a rare ZNF532-NUTM1 fusion. Virchows Arch 480:887\u2013897. https:\/\/doi.org\/10.1007\/s00428-021-03253-9","journal-title":"Virchows Arch"},{"key":"4621_CR9","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1111\/1759-7714.13648","volume":"11","author":"YA Cho","year":"2020","unstructured":"Cho YA, Choi YL, Hwang I, Lee K, Cho JH, Han J (2020) Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: a single-institute experience of 10 cases. Thorac Cancer 11:3205\u20133212. https:\/\/doi.org\/10.1111\/1759-7714.13648","journal-title":"Thorac Cancer"},{"key":"4621_CR900","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1016\/j.cllc.2020.10.016","volume":"22","author":"A Davis","year":"2021","unstructured":"Davis A, Mahar A, Wong K, Barnet M, Kao S (2021) Prolonged disease control on nivolumab for primary pulmonary NUT carcinoma. Clin Lung Cancer 22:e665\u2013e667. https:\/\/doi.org\/10.1016\/j.cllc.2020.10.016","journal-title":"Clin Lung Cancer"},{"key":"4621_CR10","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.jtocrr.2021.100249","volume":"2","author":"AA Elegbede","year":"2021","unstructured":"Elegbede AA, Gibson AJ, Fung AS, Cheung WY, Dean ML, Bebb DG et al (2021) A real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with extensive-stage SCLC in Canada. JTO Clin Res Rep 2:100249. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100249","journal-title":"JTO Clin Res Rep"},{"key":"4621_CR11","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/PAS.0b013e318258f03b","volume":"36","author":"AG Evans","year":"2012","unstructured":"Evans AG, French CA, Cameron MJ, Fletcher CD, Jackman DM, Lathan CS et al (2012) Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. Am J Surg Pathol 36:1222\u20131227. https:\/\/doi.org\/10.1097\/PAS.0b013e318258f03b","journal-title":"Am J Surg Pathol"},{"key":"4621_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nrc3659","volume":"14","author":"C French","year":"2014","unstructured":"French C (2014) NUT midline carcinoma. Nat Rev Cancer 14:149\u2013150. https:\/\/doi.org\/10.1038\/nrc3659","journal-title":"Nat Rev Cancer"},{"key":"4621_CR13","first-page":"304","volume":"63","author":"CA French","year":"2003","unstructured":"French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA (2003) BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 63:304\u2013307","journal-title":"Cancer Res"},{"key":"4621_CR14","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/onc.2013.126","volume":"33","author":"AR Grayson","year":"2014","unstructured":"Grayson AR, Walsh EM, Cameron MJ, Godec J, Ashworth T, Ambrose JM et al (2014) MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene 33:1736\u20131742. https:\/\/doi.org\/10.1038\/onc.2013.126","journal-title":"Oncogene"},{"key":"4621_CR15","doi-asserted-by":"publisher","DOI":"10.21037\/acr-21-35","author":"R Gupta","year":"2022","unstructured":"Gupta R, Mumaw D, Antonios B, Anusim N, Dhulipalla SP, Stender M et al (2022) NUT midline lung cancer: a rare case report with literature review. AME Case Rep. https:\/\/doi.org\/10.21037\/acr-21-35","journal-title":"AME Case Rep"},{"key":"4621_CR16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/PAS.0b013e318198d666","volume":"33","author":"H Haack","year":"2009","unstructured":"Haack H, Johnson LA, Fry CJ, Crosby K, Polakiewicz RD, Stelow EB et al (2009) Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol 33:984\u2013991. https:\/\/doi.org\/10.1097\/PAS.0b013e318198d666","journal-title":"Am J Surg Pathol"},{"key":"4621_CR17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/PAI.0000000000000781","volume":"28","author":"M He","year":"2020","unstructured":"He M, Chernock R, Zhou S, Gondim M, Dehner LP, Pfeifer JD (2020) Tumor mutation burden and checkpoint immunotherapy markers in NUT midline carcinoma. Appl Immunohistochem Mol Morphol 28:495\u2013500. https:\/\/doi.org\/10.1097\/PAI.0000000000000781","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"4621_CR18","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/his.14306","volume":"78","author":"YP Hung","year":"2021","unstructured":"Hung YP, Chen AL, Taylor MS, Huynh TG, Kem M, Selig MK et al (2021) Thoracic nuclear protein in testis (NUT) carcinoma: expanded pathological spectrum with expression of thyroid transcription factor-1 and neuroendocrine markers. Histopathology 78:896\u2013904. https:\/\/doi.org\/10.1111\/his.14306","journal-title":"Histopathology"},{"key":"4621_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12957-020-02065-6","volume":"18","author":"S Joel","year":"2020","unstructured":"Joel S, Weschenfelder F, Schleussner E, Hofmann GO, Weschenfelder W (2020) NUT midline carcinoma in a young pregnant female: a case report. World J Surg Oncol 18:290. https:\/\/doi.org\/10.1186\/s12957-020-02065-6","journal-title":"World J Surg Oncol"},{"key":"4621_CR20","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1634\/theoncologist.2018-0477","volume":"24","author":"M Jung","year":"2019","unstructured":"Jung M, Kim S, Lee JK, Yoon SO, Park HS, Hong SW et al (2019) Clinicopathological and preclinical findings of NUT carcinoma: a multicenter study. Oncologist 24:e740\u2013e748. https:\/\/doi.org\/10.1634\/theoncologist.2018-0477","journal-title":"Oncologist"},{"key":"4621_CR21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1093\/annonc\/mdw686","volume":"28","author":"JK Lee","year":"2017","unstructured":"Lee JK, Louzada S, An Y, Kim SY, Kim S, Youk J et al (2017) Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma. Ann Oncol 28:890\u2013897. https:\/\/doi.org\/10.1093\/annonc\/mdw686","journal-title":"Ann Oncol"},{"key":"4621_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03052-w","author":"S Lee","year":"2021","unstructured":"Lee S, Shim HS, Ahn BC, Lim SM, Kim HR, Cho BC et al (2021) Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-021-03052-w","journal-title":"Cancer Immunol Immunother"},{"key":"4621_CR23","doi-asserted-by":"publisher","first-page":"690115","DOI":"10.3389\/fonc.2021.690115","volume":"11","author":"X Li","year":"2021","unstructured":"Li X, Shi H, Zhang W, Bai C, He M, Ta N et al (2021) Immunotherapy and targeting the tumor microenvironment: current place and new insights in primary pulmonary NUT carcinoma. Front Oncol 11:690115. https:\/\/doi.org\/10.3389\/fonc.2021.690115","journal-title":"Front Oncol"},{"key":"4621_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","volume":"31","author":"AS Mansfield","year":"2020","unstructured":"Mansfield AS, Ka\u017carnowicz A, Karaseva N, S\u00e1nchez A, De Boer R, Andric Z et al (2020) Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial. Ann Oncol 31:310\u2013317. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.021","journal-title":"Ann Oncol"},{"key":"4621_CR25","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.2169\/internalmedicine.0434-17","volume":"57","author":"N Maruyama","year":"2018","unstructured":"Maruyama N, Hikiishi A, Suginaka M, Furukawa K, Ogawa K, Nakamura N et al (2018) Nuclear protein in testis carcinoma of the thorax. Intern Med 57:3169\u20133173. https:\/\/doi.org\/10.2169\/internalmedicine.0434-17","journal-title":"Intern Med"},{"key":"4621_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7812\/TPP\/20.093","volume":"25","author":"M Pan","year":"2020","unstructured":"Pan M, Chang JS (2020) Durable complete remission of PD-L1 positive NUT carcinoma treated with concurrent chemotherapy and radiation. Perm J 25:1\u20133. https:\/\/doi.org\/10.7812\/TPP\/20.093","journal-title":"Perm J"},{"key":"4621_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/his.14166","volume":"77","author":"F Pezzuto","year":"2020","unstructured":"Pezzuto F, Fortarezza F, Mammana M, Pasello G, Pelosi G, Rea F et al (2020) Immunohistochemical neuroendocrine marker expression in primary pulmonary NUT carcinoma: a diagnostic pitfall. Histopathology 77:508\u2013510. https:\/\/doi.org\/10.1111\/his.14166","journal-title":"Histopathology"},{"key":"4621_CR28","doi-asserted-by":"publisher","first-page":"101184","DOI":"10.1016\/j.tranon.2021.101184","volume":"14","author":"JW Riess","year":"2021","unstructured":"Riess JW, Rahman S, Kian W, Edgerly C, Heilmann AM, Madison R et al (2021) Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. Transl Oncol 14:101184. https:\/\/doi.org\/10.1016\/j.tranon.2021.101184","journal-title":"Transl Oncol"},{"key":"4621_CR29","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D et al (2019) KEYNOTE-426 investigators. pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"4621_CR30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/JTO.0000000000000545","volume":"10","author":"LM Sholl","year":"2015","unstructured":"Sholl LM, Nishino M, Pokharel S, Mino-Kenudson M, French CA, Janne PA et al (2015) Primary pulmonary NUT midline carcinoma: clinical, radiographic, and pathologic characterizations. J Thorac Oncol 10:951\u2013959. https:\/\/doi.org\/10.1097\/JTO.0000000000000545","journal-title":"J Thorac Oncol"},{"key":"4621_CR31","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB et al (2015) WHO panel. The 2015 world Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243\u20131260. https:\/\/doi.org\/10.1097\/JTO.0000000000000630","journal-title":"J Thorac Oncol"},{"key":"4621_CR32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3389\/fonc.2020.00536","volume":"10","author":"S Wang","year":"2020","unstructured":"Wang S, Chen R, Tang Y, Yu Y, Fang Y, Huang H et al (2020) Comprehensive genomic profiling of rare tumors: routes to targeted therapies. Front Oncol 10:536. https:\/\/doi.org\/10.3389\/fonc.2020.00536","journal-title":"Front Oncol"},{"issue":"12","key":"4621_CR33","doi-asserted-by":"publisher","first-page":"631483","DOI":"10.3389\/fimmu.2021.631483","volume":"25","author":"S Wang","year":"2021","unstructured":"Wang S, Fang Y, Jiang N, Xing S, Li Q, Chen R et al (2021) Comprehensive genomic profiling of rare tumors in China: routes to immunotherapy. Front Immunol 25(12):631483. https:\/\/doi.org\/10.3389\/fimmu.2021.631483","journal-title":"Front Immunol"},{"key":"4621_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13023-020-01449-x","volume":"15","author":"XH Xie","year":"2020","unstructured":"Xie XH, Wang LQ, Qin YY, Lin XQ, Xie ZH, Liu M et al (2020) Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma. Orphanet J Rare Dis 15:183. https:\/\/doi.org\/10.1186\/s13023-020-01449-x","journal-title":"Orphanet J Rare Dis"},{"key":"4621_CR35","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1002\/cam4.4096","volume":"10","author":"M Xie","year":"2021","unstructured":"Xie M, Fu X, Wang W (2021) Clinicopathological and molecular characterizations of pulmonary NUT midline carcinoma. Cancer Med 10:5757\u20135764. https:\/\/doi.org\/10.1002\/cam4.4096","journal-title":"Cancer Med"},{"key":"4621_CR36","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1016\/S1470-2045(20)30430-7","volume":"21","author":"X Yang","year":"2020","unstructured":"Yang X, Wang D, Lin J, Yang X, Zhao H (2020) Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Lancet Oncol 21:e412. https:\/\/doi.org\/10.1016\/S1470-2045(20)30430-7","journal-title":"Lancet Oncol"},{"key":"4621_CR37","doi-asserted-by":"publisher","first-page":"700781","DOI":"10.3389\/fonc.2021.700781","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Han K, Dong X, Hou Q, Li T, Li L et al (2021) Case report and literature review: primary pulmonary NUT-midline carcinoma. Front Oncol 11:700781. https:\/\/doi.org\/10.3389\/fonc.2021.700781","journal-title":"Front Oncol"},{"key":"4621_CR38","doi-asserted-by":"publisher","first-page":"778296","DOI":"10.3389\/fonc.2021.778296","volume":"11","author":"J Zhou","year":"2022","unstructured":"Zhou J, Duan M, Jiao Q, Chen C, Xing A, Su P et al (2022) Primary thyroid NUT carcinoma with high PD-L1 expression and novel massive IGKV gene fusions: a case report with treatment implications and literature review. Front Oncol 11:778296. https:\/\/doi.org\/10.3389\/fonc.2021.778296","journal-title":"Front Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04621-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T12:20:35Z","timestamp":1689769235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04621-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4621"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04621-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]},"assertion":[{"value":"3 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}